Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 14/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | RORB | Q92753 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593201 | 0.86 | TLR8 (0.55) | TLR8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12593198 | 0.86 | TLR8 (0.55) | TLR8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL278623 | 0.85 | PSEN1 (0.40) | TLR8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12593197 | 0.84 | TLR8 (0.56) | TLR8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14570227 | 0.84 | PSEN1 (0.40) | TLR8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13471986 | 0.83 | RORA (0.48) | TLR8CNR2PGRRORARORC | |
| SCHEMBL18947670 | 0.80 | RORA (0.53) | TLR8PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL278836 | 0.80 | TP53 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL278731 | 0.80 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23665528 | 0.78 | CNR2 (0.38) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134143-B2 | 2,7-carbazolenevinylene derivatives as novel materials in producing organic based electronic devices | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2012-03-13 | — | — | US | disclosed |
| US-20070176163-A1 | 2,7-Carbazolenevinylene derivatives as novel materials in producing organic based electronic devices | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2007-08-02 | — | — | US | disclosed |
| US-20070069197-A1 | Monomers, oligomers and polymers of 2-functionalized and 2,7-difunctionalized carbzoles | UNIVERSITE LAVAL (CA) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070069197-A1 | Monomers, oligomers and polymers of 2-functionalized and 2,7-difunctionalized carbzoles | TELO2, DNMT1, DDT | TLR8 1695/4885PSEN1 4166/4885PSEN2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.